Prognostic factors in patients with advanced cholangiocarcinoma: Role of surgery, chemotherapy and body mass index

Table 1 Demographic and clinical data of 55 patients with cholangiocarcinoma

	Number of patients (%)
Age (mean ± SD)	62.6 ± 13
Range (yr)	28-91	61/39
Male/Female	34/22
Diabetes (Yes/No)	14/41	25/75
BMI (kg/m2)
< 25	18	35
25-30	16	31
≥ 30	18	35
Not available	3
History of cholelithiasis (Yes /No)	17/38	31/69
Clinical manifestations
Jaundice	40	72.7
Dark urine	34	61.8
Weight loss	24	43.6
Abdominal pain	24	43.6
Total bilirubin
< 10 mg/dL	27	49
≥ 10 mg/dL	17	31
Missing	11	20
AJCC staging
I	1
II	1
III	0
IV	49	89
Missing	4
Surgery
Yes	21	38
No	34	62
Adjuvant chemotherapy
Yes	14	25
No	41	75

Table 2 Tumor location, size, grade, nodal and margin status and relation to survival in patients with cholangiocarcinoma

	n	Median survival (95% CI)	P
Location
Intrahepatic	10	6.23 (0.76-11.7)	0.68
Perihilar	18	11.47 (6.73-16.2)
Distal	21	9.17 (0.52-17.8)
Not available	6
Size
< 3 cm	19	3.47 (1.9-5.0)	0.31
≥ 3 cm	13	11 (4.13-17.87)
Not available	23	13
Grade
Poor	4	16.96 (8.9-25.0)	0.31
Moderate	15	11 (2.77-19.2)
Well	8	13 (0-31)
Missing	28
Margin status
Positive	7	9.9 (4.6-15.19)	0.90
Negative	14	14.3 (5.5-23.1)
Vascular invasion
Yes	7	22 (4.9-39.2)	0.78
No	14	10.2 (4.04-16.42)
Perineural involvement
Yes	10	6.2 (4.9-7.5)	0.66
No	13	11 (5.8-16.2)

Table 3 Association between clinical variables and survival in patients with cholangiocarcinoma

Variable (n)	Median survival (mo)	P (Univariate)
Age
< 50 (11)	10.23 (1.87-18.6)	0.410
≥ 50 (44)	9.17 (3.9-14.4)
Gender
Male (33)	9.17 (3.8-14.5)	0.386
Female (22)	9.9 (0.4-19.4)
Bilirubin
< 10 (27)	9.9 (3.1-16.7)	0.012
≥ 10 (17)	2.87 (1.2-4.5)
BMI
< 25 (18)	13.0 (8.5-17.6)	0.412
25-30 (16)	7.0 (3.2-10.8)
≥ 30 (18)	4.0 (0.5-7.6)
Surgery
Yes (21)	10.23 (4.82-15.64)	0.038
No (34)	8.7 (1.8-15.6)
Type of surgery
Whipple (6)	16.6 (0.0-39.4)	0.988
Hepatic lobectomy (6)	10.2 (3.9-16.6)
Bile duct excision (9)	14.3 (8.5-20.1)
Metastasis
Yes (19)	7.07 (0.0-15.83)	0.256
No (36)	9.09 (6.05-13.75)
Stenting
Yes (24)	9.9 (0.45-19.35)	0.930
No (32)	9.16 (4.6-13.7)
Chemotherapy
Yes (14)	16.96 (11.5-22.4)	0.038
No (41)	6.2 (0-12.9)
Chemotherapy in unresected patients
Yes (8)	17 (12.76-21.18)	0.001
No (25)	3.5 (1.12-5.8)

Table 4 Multivariate analysis of prognostic factors in patients with advanced cholangiocarcinoma

	Hazard’s ratio	95% CI	P
Bilirubin
< 10	1	1.13-0.52	0.023
≥ 10	2.421
Surgery
No	1	0.27-1.38	0.238
Yes	0.611
Chemotherapy
No	1	0.16-0.92	0.038
Yes	0.383